Wells Fargo Maintains Overweight on Nevro, Lowers Price Target to $86
Wells Fargo analyst Lawrence Biegelsen maintains Nevro (NYSE:NVRO) with a Overweight and lowers the price target from $90 to $86.
Recap: Nevro Q2 Earnings
Nevro (NYSE:NVRO) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Nevro beat estimated earnings by 13.41%, reporting an EPS of $-0.71 versus an estimate of $-0.82.
Clinical Data Presented at American Diabetes Association 82nd Scientific Sessions Reinforce Significant and Durable Benefits of Nevro’s HFX 10 kHz Therapy
Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the results from data presentations at
Expert Ratings for Nevro
Over the past 3 months, 6 analysts have published their opinion on Nevro (NYSE:NVRO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Morgan Stanley Maintains Equal-Weight on Nevro, Lowers Price Target to $55
Morgan Stanley maintains Nevro (NYSE:NVRO) with a Equal-Weight and lowers the price target from $74 to $55.
Nevro’s Return On Capital Employed Overview
Benzinga Pro data, Nevro (NYSE:NVRO) reported Q1 sales of $87.84 million. Earnings fell to a loss of $34.33 million, resulting in a 13.91% decrease from last quarter.
Where Nevro Stands With Analysts
Nevro (NYSE:NVRO) has observed the following analyst ratings within the last quarter:
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.